Status:

ACTIVE_NOT_RECRUITING

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Lead Sponsor:

Tracon Pharmaceuticals Inc.

Conditions:

Undifferentiated Pleomorphic Sarcoma

Myxofibrosarcoma

Eligibility:

All Genders

12+ years

Phase:

PHASE2

Brief Summary

This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in ...

Detailed Description

This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in ...

Eligibility Criteria

Inclusion

  • Histologically confirmed locally advanced or metastatic undifferentiated pleomorphic sarcoma (UPS) or grade ≥ 2 myxofibrosarcoma (MFS)
  • Documented progression following systemic chemotherapy
  • At least one measurable lesion
  • Eastern Cooperative Oncology Group performance status of 0 or 1
  • Adequate hematologic and organ function

Exclusion

  • More than two prior lines of chemotherapy for UPS/MFS
  • Prior immune checkpoint inhibitor or immunomodulatory therapy
  • Active autoimmune disease that has required systemic treatment
  • Major surgery within 4 weeks of dosing of investigational agent
  • Active additional malignancy
  • Pericardial effusion, pleural effusion, or ascites
  • Central nervous system metastases and/or carcinomatous meningitis
  • Active hepatitis or cirrhosis
  • Interstitial lung disease
  • Unwilling to apply highly effective contraception during the study
  • Other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, contraindicate patient participation in the clinical study

Key Trial Info

Start Date :

December 9 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2024

Estimated Enrollment :

207 Patients enrolled

Trial Details

Trial ID

NCT04480502

Start Date

December 9 2020

End Date

October 1 2024

Last Update

May 17 2024

Active Locations (30)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (30 locations)

1

University of Arizona

Tucson, Arizona, United States, 85721

2

University of California, Los Angeles

Los Angeles, California, United States, 90095

3

Sarcoma Oncology Research Center

Santa Monica, California, United States, 90403

4

Stanford University

Stanford, California, United States, 94305

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma | DecenTrialz